Stravas Drug Interactions

Transporter inhibitors: When use together, may result in elevated plasma concentrations of rosuvastatin and an increased risk of myopathy, including rhabdomyolysis.
Cyclosporine: When Rosuvastatin is used in combination with cyclosporine, the AUC of rosuvastatin is 7 times higher than that observed in healthy volunteers. Rosuvastatin is contraindicated in patients receiving concurrent cyclosporine therapy.
Protease inhibitors: Although the mechanism of drug interaction is unclear, concurrent use of protease inhibitors may significantly increase rosuvastatin exposure.
Gemfibrozil and other lipid-lowering products: When used in combination with gemfibrozil, 2-fold increase in Cmax and AUC of rosuvastatin. The combination of fenofibrate and other lipid-lowering doses (≥1 g/day) with HMG-CoA reductase inhibitors increases the risk of myopathy, possibly because they can cause myopathy when given alone.
Ezetimibe: The combination of rosuvastatin and ezetimibe 10 mg resulted in a 1.2-fold increase in rosuvastatin AUC in subjects with hypercholesterolemia.
Antacid drugs: When administered together with an antacid suspension containing magnesium hydroxide, the plasma concentration of rosuvastatin is reduced by approximately 50%. This effect can be alleviated if the antacid is administered 2 hours after administration.
Erythromycin: When combined with erythromycin, the AUC and Cmax of rosuvastatin decreased by 20% and 30%, respectively. This interaction may be due to the increased gastrointestinal motility induced by erythromycin.
Colchicine: Myopathy including rhabdomyolysis has been reported when HMG-CoA reductase inhibitors, including rosuvastatin, are combined with colchicine. Therefore, caution should be taken when rosuvastatin is combined with colchicine.